What is the first-line treatment for ischemic heart disease?
Ischemic heart disease (ICD-11 BA6Z) is managed along two parallel tracks: controlling symptoms — particularly angina — and reducing long-term cardiovascular risk. Both American and European guidelines provide structured recommendations for how this management should be sequenced from the outset.
Treatment approach
First-line management centres on a specific class of anti-anginal medication that major international guidelines endorse as the preferred starting therapy. Disease-modifying treatment is initiated alongside it, targeting long-term outcomes as well as symptom control.
The full regimen — including companion agents, sequencing, and selection criteria — is in the structured protocol below.
Clinical goals
Successful management aims to reduce angina frequency and symptom burden, while raising the threshold at which angina appears — improving functional capacity and quality of life.
References
DOI: 10.1093/eurheartj/suaa060
- Beta-adrenergic antagonists, or beta-blockers (BBs), are the most commonly used drugs for the treatment of angina.
- The American and European guidelines for the management of SIHD, published respectively in 2012 and 2013, recognize the importance of this class of drugs and recommend their use on the front line for the treatment of angina, even in patients without history of MI or left ventricular dysfunction.
- Chronic angina therapy includes drugs that slow the progression of the disease and reduce cardiovascular events (ASA, statins) and drugs that improve symptoms and therefore the quality of life.
- Antiplatelet therapy is a cornerstone in patients with CAD and is historically represented by aspirin.
- The above mechanisms improve the balance between oxygen supply and demand and increase the threshold of appearance of angina.
- All these drugs have been proven to reduce significantly angina.
View source ↗